Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Masaru Matsuda, Senior Vice President and General Counsel of Arcutis Biotherapeutics, sold 5,016 shares of common stock on May 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On May 2, 2024, Masaru Matsuda, Senior Vice President and General Counsel of Arcutis Biotherapeutics, sold 5,016 shares of the company's common stock.
• The sale was executed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units.
• The shares were sold at a weighted average price of $8.7378, with individual transactions ranging from $8.47 to $9.07.
• Following the transaction, Matsuda directly owns 185,408 shares of Arcutis Biotherapeutics.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice. There is no indication of any negative or positive implications for the company's performance.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is often viewed as a positive sign as it indicates the insider is not trading on inside information.

Industry Context

Sales of shares by company executives are a normal part of corporate activity. It is important to consider the context of the sale, such as the reason for the sale and whether it was conducted under a pre-arranged trading plan.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the reason for the sale and the relatively small number of shares involved.

Key Dates